The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Oral paricalcitol (19-nor-1,25-Dihydroxyvitamn D2) in women with metastatic breast cancer receiving taxanes or ixabepilone: A feasibility trial.
J. Lawrence
No relevant relationships to disclose
J. Lovelace
No relevant relationships to disclose
S. A. Akman
No relevant relationships to disclose
S. A. Melin
No relevant relationships to disclose
L. D. Case
No relevant relationships to disclose
G. Schwartz
No relevant relationships to disclose